prof. dr. Fritz Offner
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Fritz.Offner@UGent.be
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.
-
Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).
-
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial
-
- Journal Article
- A1
- open access
The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma
-
- Conference Paper
- open access
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
- Conference Paper
- open access
Characterization of Duvelisib in Patients with Refractory Marginal Zone Lymphoma: Data from the Phase 2 DYNAMO Trial
-
- Conference Paper
- open access
Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial
-
- Conference Paper
- open access
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia
-
- Journal Article
- open access
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
-
Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)